{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Bilen O"],"funding":["Bristol-Myers Squibb"],"pagination":["e005502"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12915557"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["19(1)"],"pubmed_abstract":["Background
Mavacamten has been shown to improve cardiac function and symptoms in patients with symptomatic (New York Heart Association class II-III) obstructive hypertrophic cardiomyopathy (HCM). Clinical studies suggest that mavacamten monotherapy is efficacious and has a favorable safety profile, but limited evidence exists regarding monotherapy in real-world studies. This analysis aimed to describe the effectiveness and safety outcomes of mavacamten monotherapy in the real-world COLLIGO-HCM study (Mavacamten ObservationaL Evidence Global Consortium in Hypertrophic Cardiomyopathy).Methods
Patient-level data recorded between April 2022 and February 2025 at 7 sites across 5 countries were extracted. Adult patients with a diagnosis of HCM from 2018 onwards were eligible for "],"journal":["Circulation. Genomic and precision medicine"],"pubmed_title":["Mavacamten Monotherapy in Real-World Patients With Obstructive Hypertrophic Cardiomyopathy: Evidence From COLLIGO-HCM."],"pmcid":["PMC12915557"],"funding_grant_id":["N/A"],"pubmed_authors":["Sandler B","Pruett C","MacNamara JP","Maksabedian Hernandez EJ","Han X","Tian D","Burford E","Adler A","Maor E","Li L","Patel N","Arora P","Bilen O","Schuler P","COLLIGO-HCM investigators","Arora G","Paratz E","Gold M","Arad M","Bastiaenen R"],"additional_accession":[]},"is_claimable":false,"name":"Mavacamten Monotherapy in Real-World Patients With Obstructive Hypertrophic Cardiomyopathy: Evidence From COLLIGO-HCM.","description":"Background
Mavacamten has been shown to improve cardiac function and symptoms in patients with symptomatic (New York Heart Association class II-III) obstructive hypertrophic cardiomyopathy (HCM). Clinical studies suggest that mavacamten monotherapy is efficacious and has a favorable safety profile, but limited evidence exists regarding monotherapy in real-world studies. This analysis aimed to describe the effectiveness and safety outcomes of mavacamten monotherapy in the real-world COLLIGO-HCM study (Mavacamten ObservationaL Evidence Global Consortium in Hypertrophic Cardiomyopathy).Methods
Patient-level data recorded between April 2022 and February 2025 at 7 sites across 5 countries were extracted. Adult patients with a diagnosis of HCM from 2018 onwards were eligible for ","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Feb","modification":"2026-07-16T06:58:12.919Z","creation":"2026-07-09T13:10:59.673Z"},"accession":"S-EPMC12915557","cross_references":{"pubmed":["41212168"],"doi":["10.1161/CIRCGEN.125.005502"]}}